Seung‐Hwan Kwon

This study develops an siRNA-antibody conjugate targeting IGF1R for systemic and CNS delivery, showing effective knockdown in multiple tissues and good tolerability.

This paper presents preclinical data on a bispecific antibody, SAR446159, designed to target alpha-synuclein aggregates and cross the blood-brain barrier for treating synucleinopathies.

This paper identifies NOD2/RIPK2 signaling as a key driver of neuroinflammation in Parkinson's disease, showing that pathological α-synuclein activates this pathway in microglia, leading to neurodegeneration and that targeting NOD2 or RIPK2 protects dopamine neurons.

This study investigates the effects of Gba1 E326K mutation in mice, showing increased microglia activation, neuroinflammation, and dopaminergic neurodegeneration.

The paper identifies complement and coagulation cascade pathways as significantly altered in two Parkinson's disease mouse models through proteome analysis.